Loading organizations...
Based in Boston, Massachusetts, Ascidian Therapeutics is a biotechnology company that develops RNA exon-editing therapies to treat severe genetic diseases by precisely replacing mutated exons via trans-splicing. The proprietary platform targets large genes with high mutational variance, focusing primarily on ophthalmology, neurological disorders, and rare conditions such as Stargardt disease. The enterprise has raised $90 million in total Series A funding from lead investor Apple Tree Partners, and it secured a strategic collaboration with Roche featuring $42 million in upfront payments alongside up to $1.8 billion in potential milestones. Led by executives including former CEO Romesh Subramanian, the organization received FDA clearance in early 2024 for its Investigational New Drug application for ACDN-01, marking the first RNA exon-editing therapy to enter human clinical trials. Ascidian Therapeutics was founded in 2020 by Michael Ehlers and Apple Tree Partners.
Ascidian Therapeutics has raised $90.0M across 2 funding rounds.
Ascidian Therapeutics has raised $90.0M in total across 2 funding rounds.
Ascidian Therapeutics has raised $90.0M in total across 2 funding rounds.
Ascidian Therapeutics's investors include Seth Harrison, Michael Ehlers, Spiros Liras, ATP (Apple Tree Partners), ATP, Seth L. Harrison.
Ascidian Therapeutics has raised $90.0M across 2 funding rounds. Most recently, it raised $40.0M Series A in November 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2023 | $40M Series A | Seth Harrison | Michael Ehlers, Spiros Liras, ATP (apple Tree Partners) | Announced |
| Oct 1, 2022 | $50M Series A | ATP | Seth L. Harrison, ATP (apple Tree Partners) | Announced |
Ascidian Therapeutics is a clinical-stage biotechnology company developing exon-editing RNA therapeutics to address the underlying genetic causes of diseases by precisely rewriting RNA exons.[1][2][3][4] The company builds RNA exon editors that replace mutated exons via pre-mRNA trans-splicing, producing full-length functional proteins while maintaining native gene expression, serving patients with retinal, neurological, neuromuscular, and genetically defined diseases like Stargardt disease.[3][4][6][7] This solves the limitations of DNA-based gene editing, such as risks of off-target effects and challenges with large genes or high mutational variance, by enabling one-time dosing with durable effects.[4][6][7] Ascidian shows strong growth momentum as a clinical-stage player, with its lead candidate ACDN-01 advancing into the STELLAR Phase 1/2 trial for Stargardt disease and other ABCA4 retinopathies, alongside preclinical and discovery programs.[2][3][6]
Ascidian Therapeutics was created in 2020 by ATP, a leading life sciences venture capital firm, to incubate and advance its novel RNA exon-editing platform inspired by trans-splicing in ascidians—ancient ocean creatures that re-engineer their transcriptome.[1][4] The idea emerged from leveraging high-throughput molecular biology, computational biology, and structure-based RNA design to develop therapeutics that edit exons at the RNA level, bypassing DNA modification risks.[1][7] Early traction came from ATP's incubation support, rapidly progressing the platform to clinical-stage status with programs targeting complex genetic diseases, including an initial focus on Stargardt disease.[1][6]
Ascidian stands out in RNA therapeutics through these key strengths:
Ascidian rides the RNA therapeutics revolution, expanding beyond mRNA vaccines into precise editing tools amid surging demand for genetic disease treatments post-CRISPR limitations.[4][7] Timing is ideal as advancements in delivery (e.g., targeted AAV, nanoparticles) and computational biology enable scalable RNA platforms, while market forces like aging populations and unmet needs in retinal/neurological diseases (e.g., Stargardt affecting 1 in 10,000) drive investment.[6] By influencing the ecosystem, Ascidian pioneers "post-transcriptional editing" as a safer alternative to DNA tools, potentially broadening treatable mutations and inspiring hybrid RNA-gene therapies.[3][4]
Ascidian is poised for milestone-driven growth, with the STELLAR trial readout for ACDN-01 potentially validating exon editing in 2026–2027, followed by expansion into neuromuscular and neurological indications.[2][6] Trends like AI-optimized RNA design and improved delivery will accelerate its pipeline, while partnerships could amplify reach amid biotech's focus on one-and-done therapies. Its VC-backed origins position it to evolve from incubator to category leader, redefining RNA medicine much like ascidians reshaped vertebrate evolution—delivering a sea change in treating untreatable diseases.[1][4]
